1 BAUSCH-Health 2 Q 2024 EARNINGS AUGUST 1, 2024 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to sep ...

Exhibit 99.1 1 CH-Health | --- | --- | |---------------------|----------------------| | | | | Investor Contact: | | | | | | Garen Sarafian | | | ir@bauschhealth.com | | | (877) | 281-6642 (toll free) | | --- | --- | |-------------------------------------------|-------| | | | | Media Contact: | | | Katie Savastano | | | corporate.communications@bauschhealth.com | | | (908) 541-3785 | | BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2024 RESULTS • Second quarter consolidated revenues of $2.40 billion, up 11% on a Rep ...

Bausch Health Companies Overview Harvard Zhang, a Deputy Managing Editor of Reorg.com, posted at 10:26 a.m. on July 24 that "Bausch Health is negotiating a potential prepackaged chapter 11 bankruptcy filing." In the early afternoon, Bausch Health responded to the misleading post. The firm said that the article contained unsubstantiated rumors that included considering a bankruptcy or insolvency proceeding. BHC investors should not expect the firm would sue the reorg site for the posting. Bausch wrote, "We u ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) 2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8 (Address of Principal Executive Offices) (Zip Code) Title of each class Trading Symbol(s) Name o ...

Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participants Glen Santangelo - Jefferies Michael Nedelcovych - TD Cowen Douglas Miehm - RBC Capital Markets Umer Raffat - Evercore ISI Chi Fong - Bank of America David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings. Welcome to the Bausch Health first quarter 2024 earnings call. At this time, ...

Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -21.33%. A quarter ago, it was expected that this drugmaker would post earnings of $1.01 per share when it actually produced earnings of $1.15, delivering a surprise of 13.86%.Over the last four quarters, the company ...

BAUSCH- Health EARNINGS 1 Q 2024 MAY 2, 2024 Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separat ...

Exhibit 99.1 CH-Health "We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan®, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb. • RED-C: prevention and delay of first episode of hepatic encephalopathy ◦ Enrollment of the second global Phase 3 trial completed in April 2024. Enrollment of both global Phase 3 studies are now complete and currently in ...

Bausch Health (BHC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power o ...

The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46. Starting off this week on a sour note with a 6.9% loss -- BHC's worst daily percentage drop since September -- the stock is looking to extend its slide today, down 2.5% at $9.03 at last glance. For those curious about buying in on the dip, however, the recent pullback has BHC within one standard deviation of its 50-day moving average, a trendline with historically ...